Abstract: An additive-manufacturing resin vat system can include a resin vat, a flexible plastic film, a transparent support window, a transparent conductive coating, a support tray, and a set of metal contacts. The resin vat can carry a resin-print material mixture. The flexible plastic film can mechanically seal to a bottom of the resin vat. The transparent support window can support the flexible plastic film. The transparent conductive coating can be formed on at least one side of the transparent support window. The support tray can define an outer tray portion and an open tray interior, the outer tray portion carrying the transparent support window. The metal contacts can be carried by the outer tray portion and configured to electrically couple with the transparent conductive coating. The transparent conductive coating is configured to generate heat upon receiving an electrical current via the metal contacts.

Abstract: A photopolymer development resin base is available for use with additive manufacturing units (for example, various three-dimensional printers) to create three-dimensional (3D) printed structures. In some embodiments, the resin formula can include a monomer, oligomer, diluent, photo initiator, deflocculents, wetting agents, and dispersants, with a limit on any photo-blockers, if present at all. The photopolymer development resin base functions as a binder precursor material with the capacity to accept solid powders or liquids for UV printing, which is not configured to print “as is.

Abstract: A three-dimensional printed structure can include a photocurable resin, a sinterable material, and a plurality of elongated particles. The elongated particles are distributed within the printed structure. The elongated particles are shaped and distributed to promote porosity control (e.g., improved densification) within the structure.

Abstract: Three-dimensional (3D) printing systems include a 3D printer that includes a print bed that has one or more walls arranged to enclose a basin configured to contain a printing material. A compression plate is configured to fit slidably within, or on top surfaces of, the one or more walls of the print bed. A bottom plate forms a base of the basin and is configured to fit slidably within the one or more walls of the print bed. An elevation controller moves one or both of the compression plate and the bottom plate towards each other to apply a specified compressive force on printing material within the basin. The compression plate and the bottom plate together seal the basin sufficiently to avoid leakage of the print material from the basin.

Abstract: Three-dimensional (3D) printing systems include a 3D printer that includes a print bed that has one or more walls arranged to enclose a basin configured to contain a printing material. A compression plate is configured to fit slidably within, or on top surfaces of, the one or more walls of the print bed. A bottom plate forms a base of the basin and is configured to fit slidably within the one or more walls of the print bed. An elevation controller moves one or both of the compression plate and the bottom plate towards each other to apply a specified compressive force on printing material within the basin. The compression plate and the bottom plate together seal the basin sufficiently to avoid leakage of the print material from the basin.

Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Abstract: Stabilized radiopharmaceutical formulations are disclosed. Methods of making and using stabilized radiopharmaceutical formulations are also disclosed. The invention relates to stabilizers that improve the radiostability of radiotherapeutic and radiodiagnostic compounds, and formulations containing them. In particular, it relates to stabilizers useful in the preparation and stabilization of targeted radiodiagnostic and radiotherapeutic compounds, and, in a preferred embodiment, to the preparation and stabilization of radiodiagnostic and radiotherapeutic compounds that are targeted to the Gastrin Releasing Peptide Receptor (GRP-Receptor).

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.

Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.

Abstract: Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the ?, ?, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

Abstract: A vial enshrouded or contained in a protective covering which prevents emission of radiation form the vial contents, shielding the environment and personnel from irradiation. The vial optionally has a V-shaped bottom to allow withdrawal of a maximal amount of the fluid without inverting the vial. The vial is equipped with a vial access adapter having a fluid withdrawal spike which extends in to the V-shaped bottom. The vial access adapter may be vented or non-vented.

Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Abstract: Radiopharmaceutical compounds are disclosed having a radionuclide chelating moiety and a targeting ligand, and optionally a linker. Formulations of compositions useful for making the radiopharmaceutical compounds contain a chelating ligand, a reducing agent, an exchange ligand and a stabilizer.

Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Abstract: The present invention provides, inter alia, peptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.